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ABSTRACT 
Donation after circulatory death (DCD) is being used to increase the number of transplantable 
organs. The role and timing of steroids in DCD donation and ex-vivo lung perfusion (EVLP) 
has not been thoroughly investigated. In this study, we investigated the effect of steroids on 
warm-ischemic injury in a porcine model (n=6/group). Following cardiac arrest, grafts were 
left untouched in the donor (90 minutes warm ischemia). Graft function was assessed after 6 
hours of EVLP. In MP-group, 500 mg methylprednisolone was given prior to cardiac arrest 
and during EVLP. In CONTR-group no steroids were added. Median lung compliance (13 
ml/cmH20) was significantly better preserved in CONTR than in MP group (30.5 ml/cmH20). 
Also, median wet-to-dry-weight (6.11 vs 6.94) and CT-density (182.5 vs 352.9 g/L) were 
significantly better in MP-group than in CONTR-group, respectively. There was no 
difference in oxygenation and pulmonary vascular resistance. Perfusate cytokine analysis 
showed a significant reduction in IL-1β, IL-8, IFN-α, IL-10, TNF-α and IFN-γ in MP. 
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Cytokines in bronchoalveolar lavage were not decreased except for IFN-gamma. We 
demonstrated that warm-ischemic injury in DCD donation can be attenuated by steroids when 
given prior to warm ischemia and during EVLP. Ethical context of donor preconditioning 
should be discussed further.  
 
INTRODUCTION 
Lung transplantation remains the only life-saving treatment option for patients suffering from 
end-stage pulmonary disease. Due to its success, lung transplant programs worldwide are 
increasing with over 4000 lung transplants procedures performed annually (1). However, 
there is an on-going disparity between the number of patients on the waiting list and the 
number of good quality donor organs for transplantation. This leads to increased waiting 
times and a persistent mortality on the waiting list as high as 15% (2).  
Because of this organ shortage, other sources of organ recovery besides the classical brain-
dead donor (DBD) are being addressed nowadays. Over the years, organ donation after 
circulatory death (DCD) has been re-introduced in transplant programs (3–5) with a marked 
increase since 2001. On average only 7% of all lung grafts are derived from DCD donors 
according to the latest registry analysis; however in some programs this reaches up to 32% 
(3). Generally, DCD donation is classified into two main categories and further subdivided 
following the Maastricht classification (6). In uncontrolled DCD donation the patient is found 
with circulatory arrest, is dead upon arrival or dies after unsuccessful resuscitation. 
Controlled DCD donors represent patients who die after a switch-off of mechanical, 
ventilated or organ-perfusion supported therapies or when circulatory arrest occurs 
prematurely in a DBD donor. To optimise lung preservation and limit the impact of warm 
ischemic injury, several strategies have been explored. Topical cooling by insertion of chest 
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tubes can be applied in the controlled setting, but is mostly used in uncontrolled DCD 
donation (7,8). In controlled donation the current clinical practice includes rapid flush 
perfusion (antegrade in the donor and retrograde at the back-table after organ recovery) (9). 
Pre-arrest interventions are mainly limited to heparinisation if legally authorized. This can 
theoretically be beneficial as confirmed by experimental data (10). However, clinical studies 
comparing strategies with and without heparin are lacking. In fact, several centres report 
good outcome without pre-arrest heparinisation (11). These centres do use a retrograde flush 
in its heparin-free scenario which also seems protective (12).  
In all scenarios, DCD organs suffer from a variable period of warm ischemia which could 
lead to increased ischemia-reperfusion injury and a reduction in organ quality. The tolerable 
length of this warm ischemic interval for lungs can be extended up to 60-90 minutes (13,14). 
To assess organ quality of lungs donated by a DCD donor prior to transplantation, ex-vivo 
lung perfusion (EVLP) has been developed (15). With this technique of machine perfusion, 
lungs are perfused by a pump and ventilated under normothermic conditions. During EVLP, 
lungs can be physiologically evaluated and nowadays new imaging techniques can even be 
applied to fully assess the organ of previously unknown quality (16). Since the introduction 
of EVLP in 2001 by Steen et al (17) there is the actual potential to evaluate the donor organ 
prior to transplantation. This is especially recommended in uncontrolled DCD donation 
programs where outcomes are better when EVLP is applied (8). Currently, in only 12% of 
controlled DCD, EVLP is clinically applied (3). Some groups do report better outcome in 
controlled DCD donation (18) when lungs have been perfused and evaluated on EVLP. 
Therefore it may be advisable to consider this technique as a platform to assess the risk for 
severe ischemia-reperfusion injury (IRI) to decide on the optimal preservation strategy based 
on physiological evaluation. This opens up the ability to even recondition donor lungs of 
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unknown or inferior quality prior to transplantation. Hereby, an increase in available donor 
organs with optimal quality is expected (19,20).  
Steroids are among the most potent anti-inflammatory and immunosuppressive agents. In the 
airways, they bind to the glucocorticosteroid receptors which are ubiquitously expressed in 
all cells througout the airways. After translocation to the cell nucleus, they inhibite nuclear 
factor kappa B (NFκ-B) activation followed by blockage of pro-inflammatory genes (21–23). 
Therefore, steroids are of particular interest in ischemia-reperfusion injury remodeling. They 
are already a component of the perfusate used in the majority of EVLP protocols (15). 
However, the exact role of steroids during EVLP has never been elucidated and comparative 
data of EVLP with- and without methylprednisolone is lacking. Besides ex-vivo 
administration of steroids, these immunomodulatory drugs can also be administrated to the 
donor. Most brain-dead patients are now treated with steroids before procurement of the 
organs. The rationale to add steroids in the donor is to block the upregulation of several pro-
inflammatory cytokines during the onset of brain death and improvement of hemodynamic 
instability following adrenal insufficiency  (24). The evidence, however, is not robust based 
on a recent meta-analysis (25). In addition, besides these potential benefits in DBD donors, 
their role in warm ischemic injury and DCD donation has never been investigated. 
Nevertheless, over 90% of centres using DCD organs report that steroids are applied prior to 
circulatory arrest (3). 
We aimed to investigate the role of steroids in DCD lung donation to protect against warm 
ischemia-reperfusion injury. Therefore, in this study, we hypothesized that administration of 
steroids prior to onset of warm ischemia and during EVLP has a beneficial impact on 
pulmonary graft function. 
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METHODS 
This experimental study was performed in compliance with the Principles of Laboratory 
animal care published by the National Institute of Health Volume 25, No. 28 (revised 1996). 
Local ethics approval was obtained at the research institute (NTS P043/2014).  
DONOR PROCEDURE 
Domestic pigs Topig 20 (mean 40.75 kg) were divided into 2 groups (n=6/group). Animals 
were anesthetized with an intramuscular injection of 5 mg/kg Zoletil 100 (Virbac, Carros, 
France) and 3 mg/kg Xyl-M 2% (VMD, Arendonk, Belgium). Anaesthesia was maintained 
using 10 mg/kg/h propofol, 20 µg/kg/h fentanyl and intermittent boli of pancuronium 2mg for 
muscle relaxation. Animals were intubated with a 7.0 mm endotracheal tube and ventilated 
(Aestiva 3000; GE Healthcare Europe GmbH, Little Chalfont, UK) with a tidal volume (TV) 
of 8 ml/kg, positive end expiratory pressure (PEEP) of 5 cmH2O and FiO2 of 30%. 
Respiratory rate (RR) was adjusted to the end-tidal carbon dioxide (ETCO2) (45-55 mmHg). 
Blood pressure was monitored invasively in the right carotid artery. All animals died of 
cardiac arrest which was induced by direct electrical stimulation of the myocardium with an 
electrical pulse generator that led to ventricular fibrillation. Animals were disconnected from 
the ventilator when cardiac arrest was induced. Prior to cardiac arrest, all animals were 
heparinized with 300 IU/kg. In group 1, 500 mg Solu-Medrol (Pfizer, Brussels, Belgium) was 
given prior to induction of ventricular fibrillation (MP-group). In group 2, no steroids were 
administered to the donor animal (CONTR-group). 
Following cardiac arrest in the donor, grafts were left untouched in the deceased donor for 90 
minutes after which they were flushed antegradely with 50 ml/kg cold thromethamol-
buffered OCS Solution (Transmedics, Andover, USA). The heart-lung block was excised and 
a retrograde flush (1L thromethamol-buffered OCS solution) was performed at the back table. 
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Lungs were instrumented on ice for a short period of time (73.2 ± 7.5 min) while the XVIVO 
(Göteborg, Sweden) cannulas were secured in the pulmonary artery and atrial cuff. An 8.0-
mm ET tube was secured in the trachea. The donor procedure was performed as previously 
described (26). 
EX-VIVO LUNG PERFUSION 
After a 1-hour rewarming period and slow increase of the flow to 40% of the estimated 
cardiac output (calculated as 100 ml/kg) lungs were further perfused and evaluated for 6 
hours in total. Lungs are perfused with an acellular albumin containing dextran solution. The 
production of the perfusate and technique of EVLP are performed as described previously 
(26).  In the CONTR-group, no steroids were added to the perfusate. In the MP-group, 500 
mg Solu-Medrol ® (Pfizer, Brussels, Belgium) was added to the perfusate to continue the 
steroid-exposure to the preconditioned grafts in the MP-group in order to investigate the 
maximal effect of steroids to DCD-grafts. 
During 6 hours of EVLP we monitored dynamic airway compliance (Compl), oxygenation 
(PaO2/FiO2) and pulmonary vascular resistance (PVR) hourly. We analysed end-experimental 
parameters only to dichotomize between acceptable and non-acceptable lungs. 
TISSUE SAMPLING 
At the end of the experiment, tissue samples were taken for histological evaluation and wet-
to-dry-weight (W/D) ratio calculation (after 48hrs in the oven at 80°C). Pathology samples 
are scored by a blinded pathologist for neutrophilia, congestion and presence of eosinophils. 
Broncho-alveolar lavage with 2 times 30 cc saline 0.9% was performed in the right middle 
lobe. Pooled fractions were returned and the supernatant was analysed with a porcine 
multiplex ELISA kit for IL-1β, IL-4, IL-8, IL-10, IFN-γ, IFN-α and TNF-α according to the 
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manufacturer’s protocol (Thermo Fisher Scientific Inc, Massachusetts, USA). Also perfusate 
samples from the end of the experiment were analysed with the same ELISA analysis. The 
left lung was inflated at 25 cmH2O, frozen solid in the fumes of liquid nitrogen and scanned 
with Siemens Somaton CT scanner. Lung mass, volume, and density were measured on the 
basis of the CT-scan, using imaging software (HorosTM) in which the lung is manually 
delineated and the number of voxels and mean density of the voxels within the volume is 
determined (27). 
STATISTICAL ANALYSIS 
All data are expressed as median with IQ range when depicting physiological variables in 
time or as a scatter plot with median and IQ range when comparing variables at the end of the 
experiment (GraphPad Prism 4, GraphPad Software Inc, La Jolla, USA). Permutation tests 
were conducted in R (R Foundation, Vienna, Austria) using the “coin” package to compare 
data at the end of EVLP. Baseline parameters of the donor animals are described as median 
(25% QI – 75% QI) and are analysed with the same permutation test.  
In cases where lungs could not sustain the full 6 h of EVLP, data points recorded in the next 
hours after the premature end of EVLP were considered the same as the last data point 
available to allow comparison at all evaluation points. Therefore, at the end of EVLP the last 
available data point is included for the statistical analysis. Graft survival on EVLP is analysed 
with a log rank test in GraphPad Prism 4 (GraphPad Software Inc, La Jolla, USA). 
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RESULTS 
GROUPS 
Baseline parameters are illustrated in TABLE 1. 
FUNCTIONAL ASSESSMENT OF PULMONARY GRAFTS DURING EVLP 
FIGURE 1A depicts the change of dynamic airway compliance over time (median – IQ 
range). It is similar at the onset of evaluation (starting after 1 hours of EVLP). After the first 
recruitment manoeuvre at 1.5hrs perfusion, compliance increased in both groups followed by 
a gradual decrease. When comparing the dynamic airway compliance at the end of EVLP 
(FIGURE 1B), we noted that it was significantly better preserved in the MP group (Median 
Compl 13 ml/cmH20 in CONTR vs 30.5 ml/cmH20 in MP group; p=0.0304). 
Figure 1C depicts the change in oxygenation (evaluated by PaO2/FiO2) over time (median – 
IQ range).  PaO2/FiO2 decreased in both groups and was also not significantly different when 
comparing it at the end of the experiment (Median PaO2/FiO2 486.7 in CONTR vs 430.4 in 
MP group; p=0.5887) (FIGURE 1D).  
FIGURE 1E depicts the change in pulmonary vascular resistance (PVR) over time (median – 
IQ range). PVR is low in both groups at the first evaluation moment (1 hour perfusion). 
During the experiment, PVR slowly increases in both groups. When comparing PVR at the 
end of EVLP (FIGURE 1F), we observed a similar PVR in both groups (Median PVR 473.7 
dynes*sec*cm-5 in CONTR vs 430.4 dynes*sec*cm-5 in MP group; p=0.8182). 
For all experiments in the MP group, grafts could be perfused for 6 hours. In the CONTR-
group however, there was a drop-out of 3 experiments where perfusion was ended on 3.75, 
4.0 and 4.5hrs respectively due to excessive oedema formation (FIGURE 2). The superior 
survival of the grafts in the MP group nearly reaches significance (p=0.055). 
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ASSESSMENT OF PULMONARY OEDEMA 
A high W/D weight (median 6.94) is observed in the CONTR-group, and a low W/D weight 
(median 6.11) in the MP group. W/D weight ratio is significantly lower (p=0.0200) in the 
group that received methylprednisolone (FIGURE 3A). Density measurements on CT-scan 
confirmed this excess of extravascular lung water accumulation and showed a significantly 
higher (p=0.0022) density in the CONTR-group (median 352.9 g/L) compared to the MP-
group (median 182.5 g/L) (FIGURE 3B). Septal thickening and severe lung oedema can 
clearly be visualised in the CONTR-group (FIGURE 3C) in comparison to the MP-group 
(FIGURE 3D). 
HISTOLOGY 
Histological analysis did not reveal any significant differences in congestion (p=0.5798), 
neutrophil invasion (p=0.1252) and membrane disruption (p=0.2077) compared to the 
CONTR-group. 
IMMUNOLOGICAL EVALUATION 
Porcine multiplex analysis of the perfusate sample at the end of EVLP (FIGURE 4) showed a 
median IL-1B level of 124.6 pg/ml in the CONTR vs 39.8 pg/ml in the MP group 
(p=0.0022); a median IFN-alpha level of 94.6 pg/ml in the CONTR vs 0.66 pg/ml in the MP 
group (p=0.0037); a median TNF-alpha level of 3181 pg/ml in the CONTR vs 225.8 pg/ml in 
the MP group (p=0.0081); a median IL-10 level of 94.6 pg/ml in the CONTR vs 0.66 pg/ml 
in the MP group (0.0037) and a median IFN-gamma level of 2.83 pg/ml in the CONTR vs 
0.08 pg/ml in the MP group (p=0.0050). IL-8 was above detection limit in the CONTR-group 
(highest standard depicted), but low in the MP group (median 45.32 pg/ml). IL-4 was below 
the detection limit. 
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Multiplex analysis of the BAL fluid at the end of EVLP showed a median IL-1B level of 
36.45 pg/ml in the CONTR vs 34.21 pg/ml in the MP group (p=0.2876); a median IFN-alpha 
level of 0.36 pg/ml in the CONTR vs 0.38 pg/ml in the MP group (p=0.5582); a median 
TNF-alpha level of 233.8 pg/ml in the CONTR vs 105.4 pg/ml in the MP group (p=0.1727) 
and a median IL-8 level of 174.2 pg/ml in the CONTR vs 61.8 pg/ml in the MP group 
(p=0.0649). IFN-gamma was significantly lower (p=0.0157) in the MP-group (median 0.05 
pg/ml) compared to the CONTR group (median 0.1 pg/ml). IL-10 and IL-4 were both below 
the detection limit. 
  
DISCUSSION 
We report our experimental findings on the role of steroids in a DCD model of organ 
donation. To our knowledge, this is the first experimental report on the use of steroids in a 
DCD donor. We demonstrated that administration of steroids prior to warm ischemia and 
during EVLP evaluation significantly improved lung function, lung oedema and reduced a 
subset of inflammatory markers 
By giving steroids to the donor prior to the onset of warm-ischemia and further exposure to 
steroids during EVLP we observed improved lung compliance at the end of EVLP. 
Pulmonary vascular resistance and oxygenation did not differ between both groups. However, 
it has previously been advocated that compliance is the best parameter to predict donor lung 
quality (28,29) since this parameter directly reflects the impact of fluid extravasation in the 
lung. Also, physiological acceptance criteria for transplantation after EVLP are not yet been 
agreed upon and other groups do advocate the use of oxygenation and pulmonary vascular 
resistance as the best evaluation parameters with excellent results after transplantation (30). 
W/D is still the golden standard for estimation of lung oedema, and in our experimental study 
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it was significantly lower in the MP-group. This could be further validated by a lower density 
measurement in the methylprednisolone group on CT-scan. The latter provides assessment of 
the whole lung surface, while a biopsy provides information only on a small portion of the 
tissue. Implementation of CT-scanning might be considered as a valuable non-invasive tool 
to measure pulmonary oedema. 
The cytokine expression profile of lungs in both groups was represented by evaluating 
cytokines in both the circulating perfusate and BAL (at the end of EVLP). Administration of 
steroids to the donor in addition with exposure to steroids during EVLP resulted in a 
decreased level of cytokine production and release, especially in the perfusate. Also, this 
reflects a reduced organ inflammation, but the role of cytokine expression on EVLP is still 
largely unknown (31). It might be that a different pattern of cytokines is expressed during ex-
vivo organ perfusion that does not completely reflect the in-vivo reperfusion situation. We 
used an acellular perfusate and the reperfusion injury observed during our set-up is mainly 
driven by resident leukocytes in the pulmonary graft. This expressed cytokine panel also 
suggest an important role for macrophage secretion. The observation that the anti-
inflammatory cytokine IL-10 was also significantly reduced indicates that we should better 
look at the balance between pro- and anti-inflammatory mediators, rather than the absolute 
concentration. 
Early outcome after lung transplantation is mainly impaired by the occurrence of severe 
primary graft dysfunction (PGD) driven by ischemia-reperfusion injury and occurs in up to 
30% of lung transplant recipients (32,33). Despite better supportive treatment options such as 
extra-corporal membrane oxygenation (34) to limit early mortality from severe PGD, this 
syndrome has a significant impact on long term outcome with an increased 90-day and 1-year 
mortality after severe PGD at 72hrs after lung transplantation (33). Also, there is an increased 
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risk to develop bronchiolitis obliterans syndrome (BOS) (32,35–37) following high-grade 
primary graft dysfunction. 
In addition, the use of DCD organs itself seems to be an increased risk factor for PGD. 
Although similar short- and long-term outcomes between DBD and DCD donors have been 
reported (38–40). Therefore it is of great interest to limit primary graft dysfunction after lung 
transplantation with a specific strategy such as steroid administration. The possible benefit of 
steroid administration is already been highlighted in brain-dead organ donation (25,41). That 
is, steroids can suppress the cytokine release during the catecholamine storm and improve 
hemodynamic stability in adrenal insufficient patients (25,42). Controlled DCD donors suffer 
an agonal phase that is unpredictable, prior to circulatory arrest. This agonal phase can add a 
large variability to the injury and is difficult to standardize. In a previous study (43) we have 
investigated the impact of different modes of death in DCD donation. We could identify that 
hypoxic arrest was more detrimental to the graft quality (44). In our current study, we have 
chosen to work with a standardized warm-ischemic porcine DCD model, with immediate 
onset of the warm ischemic interval by induction of ventricular fibrillation and disconnection 
of the ventilator (in a paralyzed animal). In this way, we could better standardize the warm-
ischemic injury (still the most important component of IRI in DCD donation). The effect of 
steroids in a controlled DCD model induced by hypoxic arrest with variable periods of warm 
ischemia is also an interesting study to conduct in the future. 
The major limitation of this study is the absence of a control group where steroids are used 
only in the donor animal. However, steroids are included in all EVLP protocols without 
convincing evidence for a beneficial effect on PGD. Based on previous preliminary data in 
our laboratory we are confident that steroid administration post-injury during EVLP only, 
cannot reverse warm ischemic injury. This is also shown from other research experiments 
where steroids are applied in the perfusate in both control and treatment groups (45–47). 
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Therefore, we believe that it is the administration of steroids to the DCD donor prior to 
circulatory arrest that is important for optimal organ preservation to alleviate warm ischemic 
damage. The administration window of pre-conditioning and preservation strategies is still 
largely unknown. In order to avoid missing any positive effect by focusing on a narrow 
window, we chose to expose the grafts to steroids throughout the whole experiment. Of 
course, further experiments should now be designed to elucidate the role of the pre-arrest 
donor treatment or treatment of the graft during EVLP only. Also, our findings need to be 
validated in a transplant model. 
In case of donation after brain dead (DBD), the advantage of using steroids has been 
investigated previously (25). However, the role of steroids in DCD donation has never been 
investigated. The reason is twofold: firstly, DCD donation has only recently become of 
higher interest and research in donor management of the DCD donor is limited and difficult 
to design. Secondly, the dead donor rule impedes on any intervention in the patient awaiting 
therapy withdrawal (controlled DCD donor) (48). However, pre-arrest therapies such as the 
use of heparin have been widely adopted in various European countries to be used in DCD 
protocols to improve organ function (3,10). Even though a relation between the 
administration of heparin and the acceleration of the dying process has not been investigated 
or demonstrated so far. We do not know if there is a relation between the dying process or 
length of the agonal phase and the administration of high dose glucocorticoids. This opens up 
the discussion about expanding donor management to DCD, as it is more and more applied in 
DBD programs.  Since steroids are not harmful to patients, we believe that steroid 
administration to DCD donors should be considered. Despite this ethical issue, the latest 
report of the DCD-registry within the International Society of Heart and Lung 
Transplantation noted that already over 90% of the participating centres give steroids to the 
DCD donor prior to declaration of dead (3). Unfortunately, there is no data available on the 
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doses, frequency and timing of steroid administration in the DCD donation process. We 
therefore do not know whether steroids were administered during the ICU admission as a 
treatment to reduce cerebral oedema, or whether it was administered to optimize donor organ 
quality. If these steroids would have been administered intentionally to optimize donor 
quality, this course of action coincides with the dead-donor rule since therapy is given to a 
patient who is not declared dead yet. Some believe that this policy could bring harm to 
transplant programs. However, others believe that once the decision for switch-off and organ 
donation has been made, one can go forward with donor management and optimization 
protocols which should be performed by an independent team to avoid any conflict of interest 
or harm to the donor. We believe that our findings should further be embedded in an ethical 
discussion to decide if pre-treatment in a DCD donor is ethically and legally acceptable. 
Donor management of a DCD donor would however be most feasible with interventions that 
are beneficial when applied only just prior to circulatory arrest (as shown in these 
experiments). This avoids implementation of complex and time-consuming management 
protocols prior to the controlled DCD procedure.  
We conclude that administration of steroids to a DCD donor and during ex-vivo lung 
perfusion attenuates warm ischemia-reperfusion injury. The role of steroids during ex-vivo 
lung perfusion only should be the subject of future research. In addition, a study on the effect 
of steroids administered only to the donor, in a controlled DCD model with hypoxic arrest 
will also add knowledge in the future. We advocate the use of steroids in clinical DCD 
programs worldwide, with caution to further introduce preconditioning strategies prior to 
declaration of death in organ donation programs. 
WORD COUNT: 3771  
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FIGURES/TABLES LEGENDS 
Table 1 – Baseline parameters of the donor animals. Data are presented as median (25% - 
75% IQR); p-value permutation test. 
 
Figure 1 – Dynamic airway compliance, oxygenation (PaO2/FiO2) and pulmonary vascular 
resistance are depicted during the 6 hours of ex-vivo lung perfusion in figure 1A, C, E 
respectively (median – IQ range) for both groups. Compliance, oxygenation and PVR are 
depicted at the end of EVLP (scatter plot median – IQ range) in figure 1 B, D, F respectively. 
A permutation test shows significantly better airway compliance at the end of EVLP in the 
MP group (p=0.0304). All other parameters are not significantly different. 
 
Figure 2 – Survival of the lung graft on EVLP, perfusion was ended when 1000ml of 
perfusate was transformed in lung oedema and ventilation was impossible. There was a trend 
in better graft survival in the MP group that only just failed to reach significance (log rank 
test p=0.055). 
 
Figure 3 – A) Wet-to-dry weight is depicted in a scatter plot with median –IQ range. A 
permutation test of the wet-to-dry weight ratio (W/D) shows significantly less lung oedema 
formation in the MP group (p=0.0200). B) Density measured on CT-scan is depicted in a 
scatter plot with median – IQ range. A permutation test shows a significantly higher density 
measurement on CT scan analysis in the CONTR group compared to the MP group 
(p=0.0022). C) CT-scan of left lower lobe in CONTR group. D) CT-scan of left lower lobe in 
MP group. 
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Figure 4 – Porcine multiplex analysis of the perfusate sample at the end of EVLP. IL-1B, 
IFN-alpha, TNF-alpha, IL-10 and IFN-gamma are all significantly lower in the CS group. 
IL-8 was above detection limit in the CONTR group, but low in the CS group. IL-4 was below 
detection limit and is not depicted. Data points are depicted in a scatter plot with median – 
IQ range and the resulting p-value of the permutation test.  
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